Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation (Q37008223)

17 August 2017

1 reference

title

Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation (English)

1 reference

stem cell transplantation

17 August 2017

1 reference

1 reference

1 reference

2

Porter DL

1 reference

17 August 2017

1

Loren AW

1 reference

17 August 2017

language of work or name

English

0 references

publication date

19 November 2007

1 reference

Bone Marrow Transplantation

17 August 2017

published in

1 reference

17 August 2017

volume

41

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

483-493

1 reference

Identical-twin bone marrow transplants for leukemia.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Immune escape mechanisms of childhood ALL and a potential countering role for DC-like leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Bl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Stem cell transplantation???harnessing of graft-versus-malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Optimizing engraftment--source and dose of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Graft-versus-leukemia reactions in allogeneic chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Treatment of murine leukaemia with x-rays and homologous bone marrow. II

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Donor leukocyte infusions in acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Extramedullary sites of leukemia relapse after transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

1 reference

7 January 2021

Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Costimulatory approaches to adoptive immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Immunotherapy of hematologic malignancy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Donor APCs are required for maximal GVHD but not for GVL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Prevention of graft versus host disease by inactivation of host antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705898

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705898

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lddu2qbznvcjjj4zhtlfrc23du

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_lddu2qbznvcjjj4zhtlfrc23du

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lddu2qbznvcjjj4zhtlfrc23du

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/lddu2qbznvcjjj4zhtlfrc23du

1 reference

30 July 2022